Abstract: The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof.
Abstract: This invention relates to a method for treatment of persistent edema in patients with exudative age-related macular degeneration. In particular, the present invention relates to treatment of wet age-related macular degeneration with intravitreal sirolimus in subjects that had an inadequate response to prior treatment with an intravitreal anti-vascular endothelial growth factor agent.
Abstract: The present disclosure provides and an agent for treating or preventing an eye disease such as presbyopia, comprising, as an active ingredient, a lipoic acid prodrug having a specified structure.
Abstract: The object of the present invention is to find a new application of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof. Isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl) aminometh yl}pyridin-2-ylamino) acetate or a salt thereof is useful as a therapeutic agent for a disease involving a greatly elevated intraocular pressure.
Type:
Grant
Filed:
March 11, 2020
Date of Patent:
May 17, 2022
Assignee:
SANTEN PHARMACEUTICAL CO., LTD.
Inventors:
Tomoko Kirihara, Atsushi Shimazaki, Najam A. Sharif
Abstract: A compound useful for preventing or treating dry eye and a medicament for preventing and/or treating dry eye comprising the same which does not substantially impact on the intraocular pressure are provided. A method of preventing and/or treating dry eye in a subject in need thereof, comprising administering a therapeutically effective amount of olodaterol or a salt thereof to the subject is also provided.
Type:
Grant
Filed:
October 28, 2021
Date of Patent:
May 17, 2022
Assignees:
SANTEN PHARMACEUTICAL CO., LTD., BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Abstract: The present invention addresses the problem of providing a novel application of meglumine or a salt thereof. The present invention is an antiseptic agent consisting of meglumine or a salt thereof, and a pharmaceutical composition comprising the antiseptic agent according to the present invention, and pertaining to: a pharmaceutical composition which does not comprise benzalkonium chloride and which is placed in a reusable container; a product that comprises the pharmaceutical composition comprising the antiseptic agent according to the present invention and a reusable container; and a method of improving the antiseptic effect of the pharmaceutical composition by comprising meglumine or a salt thereof in the pharmaceutical composition that has been placed in the reusable container.
Type:
Grant
Filed:
March 13, 2017
Date of Patent:
May 10, 2022
Assignee:
SANTEN PHARMACEUTICAL CO., LTD.
Inventors:
Toyomi Fujisawa, Koji Sakanaka, Shinya Umezaki
Abstract: To prove an optical probe that can illuminate an entire desired region at one time, even in a narrow space. An optical probe including: a linear light guide to guide light from a light source device; a planar emitter to be connected to a tip portion of the linear light guide, to emit the light; a reflective surface provided in a part of the planar emitter, to reflect the light having entered the planar emitter; and an emitting surface provided so as to face the reflective surface, to allow the light reflected by the reflective surface to be emitted from a region of the reflective surface.
Type:
Application
Filed:
January 23, 2020
Publication date:
April 28, 2022
Applicant:
SANTEN PHARMACEUTICAL CO., LTD.
Inventors:
Mitsuru KAMIKATANO, Komei OKABE, Yukie KOYAMA, Koji OHASHI
Abstract: The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof.
Abstract: In order to enable long-term stabilization of rapamycin contained in a liquid formulation, a formulation sealing vessel of the present invention includes: a sealed vessel body in which a liquid formulation containing 2% (w/w) rapamycin or a salt thereof, 94% (w/w) polyethylene glycol, and 4% (w/w) ethanol is sealed, the sealed vessel body having a volume of 0.1 mL to 1.0 mL, the liquid formulation containing no antioxidant, and the liquid formulation having a total volume of 0.02 mL to 1.0 mL.
Type:
Grant
Filed:
February 14, 2018
Date of Patent:
March 29, 2022
Assignee:
SANTEN PHARMACEUTICAL CO., LTD.
Inventors:
Sreenivasu Mudumba, Kedar Datar, Hiromitsu Shiono, Chun-jung Chu, Le An, Sudeep Rauser
Abstract: The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof.
Abstract: The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, 4-phenylbutyric acid or an ester thereof, or a pharmaceutically acceptable salt thereof.
Abstract: Provided is an ophthalmic composition comprising diquafosol or a salt thereof, a vinyl-based polymer and a cellulose-based polymer. Also provided is an agent for prevention or treatment of dry eyes, comprising diquafosol or a salt thereof, a vinyl-based polymer and a cellulose-based polymer. These solution-type aqueous eye drop for treatment of dry eye each comprises diquafosol sodium with a concentration of 3% (w/v), hydroxyethyl cellulose and polyvinylpyrrolidone having a K value of 30, and is characterized in that a single dose of 1 to 2 drops is administered by eye drop three times per day.
Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.
Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.
Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.
Abstract: A preventive or therapeutic agent for glaucoma or ocular hypertension includes a combination of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl) aminomethyl}pyridin-2-ylamino)acetate with one or more other preventive or therapeutic drugs for glaucoma or ocular hypertension, with the proviso that tafluprost is excluded.
Abstract: The present invention relates to an ophthalmic depot preparation comprising benzyl benzoate and/or benzyl alcohol and polyethylene glycol and/or dimethylsulfoxide, wherein the volume ratio of benzyl benzoate and/or benzyl alcohol to polyethylene glycol and/or dimethylsulfoxide in the ophthalmic depot preparation is 75:25 to 25:75, and the total amount of benzyl benzoate and/or benzyl alcohol and polyethylene glycol and/or dimethylsulfoxide contained is 50% (w/w) or more.
Abstract: An object of the present invention is to provide an antibody having significantly high affinity for VEGF compared to the prior art. The present invention provides a monoclonal antibody against VEGF, which binds to a vascular endothelial growth factor (VEGF) with a dissociation constant of 1×10?11 mol/L or less.
Type:
Application
Filed:
April 13, 2021
Publication date:
July 29, 2021
Applicants:
ORDER-MADE MEDICAL RESEARCH INC., SANTEN PHARMACEUTICAL CO., LTD.
Inventors:
Yasufumi MURAKAMI, Shigeki MUKOUBATA, Hirotada AKIYAMA, Koji KONOMI
Abstract: According to some embodiments, a syringe may include a barrel; a delivery conduit; a plunger seal disposed within the barrel; and a plunger rod assembly affixed to an end of the barrel, the plunger rod assembly including a first plunger rod component comprising a first linear gear, a second plunger rod component disposed at least partially in the barrel and engaged with the plunger seal, wherein the second plunger rod component comprises a second linear gear, a first rotational gear having a plurality of gear teeth for engaging the first linear gear, and a second rotational gear having a second plurality of gear teeth for engaging the second linear gear, wherein the first rotational gear is coupled to the second rotational gear such that translation of the first plunger rod component causes translation of the second plunger rod component.
Type:
Application
Filed:
April 7, 2017
Publication date:
June 17, 2021
Applicants:
Santen Pharmaceutical Co., Ltd., Congruence Medical Solutions, LLC
Abstract: The present disclosure relates to methods of treating prostate cancer by administering an effective amount of sirolimus locally to the prostate of a subject in need thereof. In particular, the present disclosure provides methods of treating prostate cancer by intratumoral injection of a liquid formulation comprising sirolimus in which the amount of sirolimus administered is well above the dosage used for preventing transplant rejection.